Medical Providers and Partner Sites

The LiBBY Study is a clinical trial designed to test the tolerability and efficacy of a Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) oral combination in reducing agitation in people at end-of-life stages with Alzheimer’s disease or other types of dementia, when compared to placebo.

The LiBBY Study is:

Phase 2





12 weeks long in the double-blind period

The active study intervention is an oral combination of THC and CBD in a digestible oil.

In comparison to THC and CBD products taken for recreational purposes or as part of state-approved medical marijuana programs, the THC and CBD combination being administered in the LiBBY Study is required by the U.S. Food and Drug Administration (FDA) to meet the standard of being a pharmaceutical grade product.

As a pharmaceutical grade product, the THC and CBD combination in the LiBBY Study is required to have a higher level of purity and a longer shelf-life than products containing non-pharmaceutical grade cannabinoids, or other active ingredients.

Contact the nearest study site for more information or to connect a patient.